Tom Blydt-Hansen

MD

Investigator, BC Children's Hospital
Director, Pediatric Multi Organ Transplant Program, BC Children's Hospital

Kidney transplantation is a life-saving treatment for children with end-stage kidney failure. A major threat to success is rejection, where the body’s immune system attacks and destroys the transplanted kidney. If rejection isn't treated early, it results in permanent injury that can lead to loss of the transplant and a return to dialysis. Currently, tests that monitor kidney function will miss early or mild rejection. Instead, we screen with repeated kidney biopsies, which are risky and unpleasant.

This research program will use proven techniques to identify signs of kidney injury and rejection in the urine of children who have had a kidney transplant. It will focus on the first year after transplant, since this is the highest risk for rejection. We will look for metabolites and chemokines that we have tested before to identify when injury or rejection is present. Metabolites are small molecules produced by our cells as part of their function or as waste products. Chemokines are a different type of molecule that is produced by our immune system to signal inflammation. We already know some of the changes that occur with rejection. We now plan to validate that the same changes are present in other Canadian children with kidney transplants.



We will ask children with a new kidney transplant and their families to participate in this study. They will provide a urine sample for analysis whenever they have a kidney biopsy and also at regular intervals after transplant. We will verify the metabolite and chemokine levels that are linked to rejection, and could predict rejection in other children. Once it has been refined, we will determine whether it improves outcome by using it as a test for real-time monitoring and limit our use of regular kidney biopsies. We hope to demonstrate that this will improve the accuracy to detect rejection early, reduce the number of biopsies and improve the health and long-term kidney function of children with a transplant.

Academic Affiliations

  • Associate Professor, , Department of Pediatrics, Faculty of Medicine, University of British Columbia
  • Research Theme: Childhood Diseases
  • Research Group(s): Clinical and Community Data, Analytics and Informatics

Contact Information

Location

4480 Oak Street, Vancouver, British Columbia, Canada, V6H 3V4

Grants

Canadian Institutes of Health Research (CIHR) “Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team).” Oct 2011-Sep 2016. PI: Schultz, Kirk Raymond, Tom Blydt-Hansen (collaborator), L.R. Brandao, R. Broady, B.C. Carleton, G. Cuvelier, M.R. Hayden, A.Y.Y. Lee, M.N.Pinsk, C.J.D. Ross, M. Spavor.

Astellas Pharma Canada, Inc. “PROBE-Adherence: Therapeutic drug exposure and outcome in pediatric kidney transplant recipients converting from twice-daily tacrolimus to daily extended-release tacrolimus.” Apr 2014- Sept 2018. PI: Tom Blydt-Hansen, Beth Foster, Ian Gibson, Julie Ho, Peter Nickerson, Atul Sharma, David Wishart.

Canadian Diabetes Association “Improving cardiovascular risk in adolescents with diabetes through research (iCARE).” Jan 2011-Dec 2014. PI: Allison Dart, Tom Blydt-Hansen (co-investigator), J. McGavock, E. Sellers, H. Dean.

Children's Hospital Foundation of Manitoba. "Pediatric Kidney Health and Transplant Education Resource: Pre-Transplant". December 2014. April 1 2015 - March 30 2016. PI: Julie Strong, Tom Blydt-Hansen.

Canadian Institutes of Health Research (CIHR) “Non-Invasive monitoring of pediatric kidney allograft injury to improve diagnosis and patient outcomes” Oct 2012- Sep 2017. PI: Tom Blydt-Hansen, Julie Ho, Peter Nickerson, David Wishart, Ian Gibson.

Canadian Institutes of Health Research (CIHR) “Canadian National Transplant Research Program (CNTRP).” Apr 2013- Mar 2018. PI: West L. Caulfield T, Hebert MJ, Humar A, Knoll G, Levings M, Mital S, Roy DC, Schultz K, Shapiro J, Tom Blydt-Hansen.

Astellas Canada "PROBE Adherence: Therapeutic drug exposure and outcome in pediatric kidney transplant recipients converting from twice-daily tacrolimus to daily extended-release tacrolimus". June 2014 - May 2018. PI: Tom Blydt-Hansen.

Related News

Every day, our researchers work towards breakthroughs to transform the lives of kids in BC and around the world. Learn about our latest innovations and advancements in child health.

Our Research

At BC Children’s, we are making discoveries that save lives and transform health care for children in our province and around the world. Our research portfolio includes basic, clinical, population, and public health research.

EXPLORE OUR RESEARCH

Stay in the Know

Sign up for compelling stories about innovative science, the doctors and researchers who turn ideas into discoveries and treatments, and the kids and families whose lives are changed.

This field is for validation purposes and should be left unchanged.